1. Executive Summary (Confidence: High)

Science Corporation is a clinical-stage medtech leader focused on solving the most profound challenges in neural engineering. Founded in 2021 by Max Hodak, the organization operates as a "full-stack" company, developing both proprietary patient-facing therapies and the vertically integrated infrastructure (Science Foundry/Ecosystem) that the broader neurotech industry relies on.

In early 2026, Science announced a massive $230 million Series C financing round, bringing its total capital to $490 million, designated for the commercialization of its PRIMA retinal implant. Clinical results published in the New England Journal of Medicine (NEJM) confirmed that 80% of blind participants using PRIMA regained the ability to read letters and words. With regulatory applications pending in both the EU and US, Science is poised to become the first BCI company to achieve a commercial-scale launch of a vision restoration device.